Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-03-28

FDA Approved: VUITY — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental application for VUITY (pilocarpine hydrochloride) submitted by AbbVie.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vuity (pilocarpine)

Snippet

SUPPL AP for VUITY (PILOCARPINE HYDROCHLORIDE)